financetom
Business
financetom
/
Business
/
Vecima Expects to Report Q2 Loss
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Vecima Expects to Report Q2 Loss
Feb 7, 2025 4:42 AM

07:16 AM EST, 02/07/2025 (MT Newswires) -- Vecima Networks ( VNWTF ) overnight Thursday said it expects to report second-quarter revenue of $71.2 million and a loss per share of $0.32 when it releases results on Feb. 13.

Results will reflect adjustments in the timing of some of its customers' cable and fiber upgrades, costs associated with job cuts, and a temporary shift in product mix, the company said.

"We...moved forward decisively with cost reductions to better align our teams and program investments with customer needs and to enhance operating efficiency going forward," said Sumit Kumar, president and chief executive officer. "Our workforce restructuring initiatives, while resulting in one-time costs that impacted Q2 results, are expected to deliver ongoing annualized cash savings of approximately $17.5 million."

With about 90% of sales in the U.S., half of which could potentially be exposed to tariffs, Vecima said it is working to mitigate potential risks.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alnylam Pharmaceuticals Reports Substantial Results of Vutrisiran's Phase 3 Study as Heart Disease Therapy
Alnylam Pharmaceuticals Reports Substantial Results of Vutrisiran's Phase 3 Study as Heart Disease Therapy
Sep 1, 2024
07:30 AM EDT, 08/30/2024 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) said Friday that detailed results of its phase 3 study of vutrisiran showed a non-significant 30% reduction in the relative risk of death up to three years in the study's monotherapy group. Vutrisiran is an investigational therapy for treating ATTR amyloidosis with cardiomyopathy, a heart disease. Shares of...
Berry Expects to Meet Production Goals for 2024
Berry Expects to Meet Production Goals for 2024
Sep 1, 2024
07:35 AM EDT, 08/30/2024 (MT Newswires) -- Berry (BRY) said Friday it expects to meet its previously issued guidance for 2024. The company previously forecast midpoint annual guidance of 25,200 barrels of oil equivalent per day. The company said it holds necessary permits to complete its drilling program planned for this year and to support activity into 2025. Berry said...
Mpox Vaccine: Emergent BioSolutions' Smallpox Vaccine Gets FDA Nod For Expanded Use For Individuals At High Risk Of Mpox Infection
Mpox Vaccine: Emergent BioSolutions' Smallpox Vaccine Gets FDA Nod For Expanded Use For Individuals At High Risk Of Mpox Infection
Sep 1, 2024
Thursday, the FDA approved Emergent BioSolutions Inc.’s supplemental Biologics License Application (sBLA) for the expansion of the indication for ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include prevention of mpox disease in individuals determined to be at high risk for mpox infection. The approval is based on previously available human safety data and data from a well-controlled animal study in...
European spirits makers jump after China drops provisional brandy measures
European spirits makers jump after China drops provisional brandy measures
Sep 1, 2024
(Reuters) - Shares in French spirit makers Remy Cointreau and Pernod Ricard rallied early on Thursday after China's commerce ministry said it will not impose provisional anti-dumping measures on brandy imported from the European Union. Shares in Remy, which jumped over 12%, were up 7% by 0851 GMT, while Pernod, which climbed as much as 12%, was up 4%. Pernod...
Copyright 2023-2026 - www.financetom.com All Rights Reserved